Dicerna Pharmaceuticals
33 Hayden Avenue
Lexington
Massachusetts
02421
United States
Tel: 617-621-8097
Website: http://www.dicerna.com/
About Dicerna Pharmaceuticals
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.
Stock Exchange: NASDAQ
Stock Symbol: DRNA
At Dicerna, we interfere to silence genes, fight rare diseases, enhance health and advance science. The goal is to leverage our GalXC™ platform and strategic partnerships to get the drug to the patient as quickly as possible. Dicerna is dedicated to our patients and committed to breaking down barriers that slow progress in rare diseases. Dicerna promotes a “no walls” philosophy that fosters a collaborative culture where all employees are valued and respected. Dicerna interferes to help patients and change lives.
279 articles with Dicerna Pharmaceuticals
-
Dicerna™ Appoints Stephen Doberstein, Ph.D., to Board of Directors
2/10/2020
Feb. 10, 2020 12:30 UTC LEXINGTON, Mass.--( BUSINESS WIRE )-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Stephen Doberstein, Ph.D., Chief Scientific Fellow at Nektar Therapeutics, Inc. (“Nektar”), to Dicerna’s board of directors (the “board”) as an independent director, effective immediately. “Steve is an accomplished
-
Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/3/2020
Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 159,700 shares of common stock and 45,500 restricted stock units to be distributed among 15 new employees, with a grant date of February 3, 2020.
-
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jan. 2, 2020
1/2/2020
Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 187,500 shares of common stock to be distributed among 15 new employees, with a grant date of January 2, 2020.
-
Dicerna™ Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
1/2/2020
Dicerna retains the right to opt into two clinical-stage programs to be derived from the discovery collaboration.
-
Dicerna™ Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection
12/19/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.
-
Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
12/17/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA)
-
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 2, 2019
12/2/2019
Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 178,500 shares of common stock to be distributed among eight new employees, with a grant date of December 2, 2019.
-
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases
11/18/2019
Collaboration to Explore Liver Cell Targets Using Dicerna’s GalXC™ Technology With the Potential to Deliver a Significant Number of Clinical Candidates
-
They will leverage Dicerna’s GalXC RNAi technology platform to explore more than 30 liver cell targets.
-
Dicerna™ to Present at the Stifel 2019 Healthcare Conference
11/13/2019
Dicerna™ Pharmaceuticals, Inc. announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 11:30 a.m. EST in New York City.
-
Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress
11/7/2019
Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial
-
Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
11/4/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial results after market close on Thursday, November 7, 2019.
-
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) on November 1, 2019
11/2/2019
Dicerna™ Pharmaceuticals, Inc., a leading developer of investigational RNA interference therapeutics, announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 209,500 shares of common stock to be distributed among 13 new employees, with a grant date of November 1, 2019
-
Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
10/31/2019
Collaboration includes discovery and development of additional therapies targeting multiple additional gene targets implicated in chronic HBV infection
-
Under the terms of the deal, Roche will pay Dicerna $200 million upfront and up to another $1.47 billion for various development, regulatory and commercial milestones.
-
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Oct. 1, 2019
10/1/2019
Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 229,000 shares of common stock to be distributed among 10 new employees, with a grant date of October 1, 2019.
-
Dicerna™ to Present at Two Upcoming Investor Conferences
9/25/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two investor conferences in October.
-
Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth
9/19/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. Mr. Gray will serve as the chairperson of the Audit Committee.
-
Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sept. 4, 2019
9/4/2019
Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 29,000 shares of common stock to be distributed among four new employees, with a grant date of September 3, 2019.
-
Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference
9/3/2019
Dicerna™ Pharmaceuticals, Inc.(Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 8:45 am EST in New York City.